- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
Patent holdings for IPC class A61K 31/53
Total number of patents in this class: 3764
10-year publication summary
|
258
|
237
|
204
|
226
|
272
|
284
|
306
|
298
|
295
|
192
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4878 |
117 |
| Shionogi & Co., Ltd. | 858 |
74 |
| Gilead Sciences, Inc. | 2037 |
50 |
| Janssen Pharmaceutica N.V. | 3395 |
48 |
| Novartis AG | 10847 |
45 |
| Servier Pharmaceuticals, LLC | 104 |
42 |
| Incyte Corporation | 1020 |
39 |
| The Regents of the University of California | 19898 |
34 |
| Takeda Pharmaceutical Company Limited | 2714 |
32 |
| Taisho Pharmaceutical Co., Ltd. | 869 |
32 |
| F. Hoffmann-La Roche AG | 7930 |
30 |
| Blueprint Medicines Corporation | 233 |
29 |
| Hoffmann-La Roche Inc. | 3414 |
27 |
| Bayer Intellectual Property GmbH | 2500 |
27 |
| Bayer Pharma AG | 1053 |
26 |
| Madrigal Pharmaceuticals, Inc. | 85 |
24 |
| Genentech, Inc. | 3971 |
23 |
| Incyte Holdings Corporation | 658 |
22 |
| Eisai R&D Management Co., Ltd. | 1236 |
22 |
| AstraZeneca AB | 2920 |
21 |
| Other owners | 3000 |